In a boost for the emerging field of epigenetics, privately-owned CellCentric Ltd of Cambridge, UK has negotiated access to one of its cancer discovery programmes to Takeda Pharmaceutical Company Ltd. The deal is valued at about $200 million. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
